Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,471 across all filing types
Latest filing 2021-11-24 Transaction in Own Shar…
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It details numerous repurchases of shares over a period, including dates, quantities, and prices. The document references compliance with the Main Board Listing Rules and GEM Listing Rules of the Stock Exchange of Hong Kong. It includes confirmations by the company secretary regarding the authorization and compliance of these repurchases. The content is focused on reporting share repurchase activity rather than announcing a new share issue or capital change. This fits the definition of a 'Transaction in Own Shares' filing, which reports the company's buyback of its own shares. The document is substantive and detailed, not merely an announcement or a brief summary, so it is not a Regulatory Filing or Report Publication Announcement. Therefore, the appropriate classification is POS (Transaction in Own Shares).
2021-11-24 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return (Equity issuer - changes in issued share capital and/or share buybacks)' and contains detailed information about repurchases of shares by Ascletis Pharma Inc. It includes dates, number of shares repurchased, prices, and confirmations related to compliance with listing rules on the Stock Exchange of Hong Kong. The document is a regulatory disclosure about share repurchases and changes in issued share capital, not a financial report or earnings release. It fits the description of a 'Transaction in Own Shares' filing, which reports the company's buyback activities. The document length is substantial and contains detailed transactional data, confirming it is not a mere announcement or certification but a full disclosure report of share repurchases.
2021-11-23 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It details repurchases of shares on various dates, quantities, and prices, confirming compliance with listing rules. The content focuses on share repurchase activities and changes in issued shares, with no financial statements or earnings data. This matches the description of a 'Transaction in Own Shares' filing, which reports company buybacks or sales of its own shares. The document length is sufficient and contains detailed transactional data, not just an announcement or certification. Therefore, the appropriate classification is POS (Transaction in Own Shares).
2021-11-19 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It details repurchases of shares on various dates, quantities, and prices, confirming compliance with listing rules. The content is focused on reporting share repurchase activity and changes in issued shares, with no financial statements or earnings data. This matches the description of a 'Transaction in Own Shares' filing, which reports company buybacks or sales of its own shares. The document is lengthy and detailed, not a brief announcement or certification, so it is not a Regulatory Filing or Report Publication Announcement. Therefore, the correct classification is POS (Transaction in Own Shares).
2021-11-18 English
VOLUNTARY ANNOUNCEMENT - FIRST SUBJECT DOSED IN THE U.S. PHASE I TRIAL FOR ASC43F ONLY HALF A MONTH AFTER IND APPROVAL BY THE U.S. FDA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding the dosing of the first subject in a U.S. Phase I clinical trial for a drug candidate. It contains no financial data, no regulatory filings, no voting results, no management changes, and no detailed financial or operational reports. The length is 3334 characters, which is relatively short and the content is clearly an announcement of a clinical trial milestone rather than a report or detailed filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a voluntary announcement about a clinical development event, which is best classified under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2021-11-18 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It details multiple repurchases of shares over a period, including dates, quantities, and prices. The document references compliance with listing rules of the Stock Exchange of Hong Kong and confirms that repurchases were made in accordance with these rules. There is no indication that this is a full financial report, earnings release, or management discussion. Instead, it is a regulatory disclosure about share repurchases and changes in capital structure. This fits the definition of a 'Transaction in Own Shares' filing, which reports company buybacks or sales of its own shares. The document length and detail confirm it is the report itself, not just an announcement or certification. Therefore, the appropriate classification is POS (Transaction in Own Shares).
2021-11-17 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.